CXCL10 and neoplasm: Whereas the addition of Cxcl10 WT sensitized CT26-Nanog tumors to PD-1 blockade and accelerated overall CD8+ T cell or tumor-reactive CD8+ cell recruitment, Cxcl10 MT had no impact on these parameters (Figure 4, J–L).